A Phase 3 interventional study of secukinumab and placebo in Juvenile Psoriatic Arthritis and Enthesitis-related Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 31 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-08-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Arthritis, Juvenile by Novartis — 6 open to participants now, 6 under way, none of them phase 3. Arthritis, Juvenile · Novartis.
Among the 18 studies in Arthritis, Juvenile by Novartis, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 9 in phase 3, and was the 9th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →6 of the 18 studies in Arthritis, Juvenile by Novartis are open now, in 10 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Ages 1+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 6–100
Novartis Pharmaceuticals · Sites in United States, Canada, France and 5 more countries
Ages 1+
Novartis Pharmaceuticals · Sites in United States
Ages 2–17
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 2–100
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9
First in 2006; this study’s year is marked. 1 started in 2017.
This study's enrollment of 86 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 43 across the 12 interventional studies, 76 across the 5 observational. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Arthritis, Juvenile by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07517250Novartis PharmaceuticalsA Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients | 2026-12-03 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
| NCT07243782Novartis PharmaceuticalsRegulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea | 2027-06-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Arthritis, Juvenile by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA). The study was divided into 3 parts (plus a post-treatment follow-up period) consisting of open-label, single-arm active treatment in Treatment Periods 1 and 3 and a randomized, double-blind, placebo controlled, event-driven withdrawal design in Treatment Period 2
TP1: All eligible subjects entered TP1 to receive 12-weeks of open-label secukinumab at a dose predicted to achieve secukinumab serum levels equivalent to adults administered a 150 mg dose regimen. Secukinumab was administered s.c. weekly for the first 4 weeks (Baseline, Weeks 1, 2, 3, 4) and then every 4 weeks thereafter. Clinical response (JIA ACR 30) was assessed at Week 12. Responders advanced to TP2 and non-responders exited the trial (early termination visit and entered into the Post-treatment follow-up period).
TP2: Subjects who were a responder (JIA ACR 30) at Week 12 entered the double-blind withdrawal TP2 and were randomized 1:1 to either secukinumab or placebo on that visit and then every 4 weeks, until either experiencing a disease flare or completion of TP2. TP2 was event driven and was planned to be closed when 33 subjects experienced a disease flare as per JIA definition. Alternatively, the study could be closed when all subjects reached the total study duration of 104 Weeks and therefore subjects who did not experience a disease flare remained in TP2 for the duration of the study and completed the study without entering into TP3
TP3: Subjects experiencing a disease flare in TP2 immediately entered TP3 to receive openlabel secukinumab every 4 weeks until total study duration of 104 weeks for that subject was achieved.
Post-treatment follow-up: The post-treatment follow-up period (lasting 12 weeks from the last study drug administration) was required for all subjects, unless they qualified and entered the secukinumab extension trial. All subjects were expected to participate in the post-treatment follow up period, except for those entering the extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active disease (ERA or JPsA) defined as having both:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
Drug: secukinumab
placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
Other: placebo
secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
Also known as: AIN457
Matched placebo to AIN457 for use in the double blind Treatment Period 2
Number of Participants Experiencing a Flare During Treatment Period 2
Survival analysis of time to flare in treatment period 2 (TP2) FAS2 Subjects are either ERA or JPsA
Time frame: From Week 12 until max Week 104
Percent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - by JIA Category
Summary of JIA ACR 30/50/70/90/100 for all subjects and each JIA category - TP1 (FAS1) The adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components * Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity. * Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor. * Functional ability: Childhood Health Assessment Questionnaire (CHAQ©) * Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity) * Number of joints with limitation of motion * Laboratory measure of inflammation: CRP (mg/L)
Time frame: baseline, week 12
Percent of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90/100 Response at Week 12 - Total
Summary of JIA ACR 30/50/70/90/100 for all subjects - TP1 (FAS1) The adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components * Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity. * Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor. * Functional ability: Childhood Health Assessment Questionnaire (CHAQ©) * Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity) * Number of joints with limitation of motion * Laboratory measure of inflammation: CRP (mg/L)
Time frame: baseline, week 12
Percent Change From Baseline for JIA ACR Core Components in TP1
Summary of JIA ACR core components for all subjects and each JIA category - Treatment period 1 Negative percent change indicates improvement Physician global assessment of disease activity (VAS mm) 0 (no disease activity) - 100 (very severe); Parent or subject global assessment of overall well-being (VAS mm) 0 (very well) - 100 (very poor); CHAQ (Childhood Health Assessment Questionnaire) 0 - 3 (most severe); Number of joints with active arthritis 0 - 73; Number of joints with limited range of motion 0 - 69.
Time frame: baseline, week 12
Percent Change in C-reactive Protein Standardized Value (mg/L)
Median Percent Change from baseline for C-reactive protein standardized value (mg/L)
Time frame: baseline, week 12
Change From Baseline Juvenile Arthritis Disease Activity Score (JADAS) Score
JADAS change from baseline for all subjects in Treatment period 1. JADAS-27 (Juvenile Arthritis Disease Activity Score in 27 joints) ranges from 0 to 57 and JADAS-71 ranges from 0 to 101 (higher scores indicate more disease activity).
Time frame: 12 weeks
Change From Baseline in Total Enthesitis Events - TP1 (FAS1)
Enthesitis swollen joint count range is 0-16. Zero is worst, and 16 is best A total of 16 entheseal sites were assessed for the presence or absence of tenderness of enthesitis. This is the mean (SD) enthesitis count (range 0-16) for FAS subjects A zero score means no enthesitis, so a zero score is better for the patient
Time frame: Baseline and week 12
Change From Baseline in Total Dactylitis Count
Summary of total dactylitis count for all subjects - TP1 (FAS1) Total dactylitis count ranges from 0 to 20. A zero score means no dactylitis, so a zero score is better for the patient
Time frame: baseline, week 12
Number of Participants With Anti-secukinumab Anitbodies
Blood samples for immunogenicity (anti-AIN457 antibodies) were taken pre-dose at the scheduled time points. In addition, if a subject discontinued from the study at any time, he/she provided a sample at the last visit. All blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein. An Electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.
Time frame: 104 weeks
Secukinumab Serum Concentration
Summary of pharmacokinetic concentrations - Treatment period 1
Time frame: baseline, week 12
Number of Participants With Inactive Disease Status for All Subjects - TP1 (FAS1)
Summary of inactive disease status for all subjects - TP1 (FAS1) Clinical inactive disease definition was adapted from the JIA ACR criteria. All were required to be met: * No joints with active arthritis * No uveitis * CRP value within normal limits for the laboratory where tested or, if elevated, not attributable to JIA * Physician's global assessment of disease activity score ≤ 10mm * Duration of morning stiffness attributable to JIA ≤15 min
Time frame: week 12
86 subjects entered TP1
| Milestone | AIN457 in TP1 | AIN457 in TP 2 | Placebo in TP2 | AIN457 in TP3 | Placebo in TP 3 |
|---|---|---|---|---|---|
| Started | 86 | 0 | 0 | 0 | 0 |
| Completed | 83 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 | 0 | 0 |
| Milestone | AIN457 in TP1 | AIN457 in TP 2 | Placebo in TP2 | AIN457 in TP3 | Placebo in TP 3 |
|---|---|---|---|---|---|
| Started | 0 | 37 | 38 | 0 | 21 |
| Completed | 0 | 31 | 36 | 0 | 16 |
| Not completed | 0 | 6 | 2 | 0 | 5 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 3 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 2 | 0 | 0 |
| Milestone | AIN457 in TP1 | AIN457 in TP 2 | Placebo in TP2 | AIN457 in TP3 | Placebo in TP 3 |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 11 | 0 |
| Completed | 0 | 0 | 0 | 10 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 |
Survival analysis of time to flare in treatment period 2 (TP2) FAS2 Subjects are either ERA or JPsA
| Participants | AIN457 in Treatment Period 2 | Placebo in TP2 |
|---|---|---|
| Number of Participants Experiencing a Flare During Treatment Period 2 | 10 | 21 |
Summary of JIA ACR 30/50/70/90/100 for all subjects and each JIA category - TP1 (FAS1) The adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components * Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity. * Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor. * Functional ability: Childhood Health Assessment Questionnaire (CHAQ©) * Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity) * Number of joints with limitation of motion * Laboratory measure of inflammation: CRP (mg/L)
| percent of participants | AIN457 in Treatment Period 1 - ERA | AIN457 in Treatment Periiod 1 - JPsA |
|---|---|---|
| ACR 30 | 86.3 (73.1 to 93.8) | 96.9 (82.0 to 99.8) |
| ACR 50 | 80.4 (66.5 to 89.7) | 96.9 (82.0 to 99.8) |
| ACR 70 | 66.7 (52.0 to 78.9) | 75.0 (56.2 to 87.9) |
| ACR 90 | 33.3 (21.1 to 48.0) | 50.0 (32.2 to 67.8) |
| ACR 100 | 27.5 (16.3 to 42.0) | 21.9 (9.9 to 40.4) |
Summary of JIA ACR 30/50/70/90/100 for all subjects - TP1 (FAS1) The adapted ACR Pediatric 30/50/70/90/100 criteria was used to determine efficacy defined as improvement from baseline of at least 30/50/70/90/100% respectively in at least 3 of the following 6 components * Physician's Global Assessment of disease activity on a 0-100 mm VAS from 0 mm = no disease activity to 100 mm = very severe disease activity. * Parent's or patient's Global Assessment of Subject's overall wellbeing on a 0-100 mm VAS from 0 mm= very well to 100 mm= very poor. * Functional ability: Childhood Health Assessment Questionnaire (CHAQ©) * Number of joints with active arthritis using the ACR definition (The ACR definition of active arthritis is any joint with swelling, or in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity) * Number of joints with limitation of motion * Laboratory measure of inflammation: CRP (mg/L)
| percent of participants | AIN457 in Treatment Period 1 - TOTAL |
|---|---|
| ACR 30 | 90.4 (81.4 to 95.4) |
| ACR 50 | 86.7 (77.1 to 92.9) |
| ACR 70 | 69.9 (58.7 to 79.2) |
| ACR 90 | 39.8 (29.4 to 51.1) |
| ACR 100 | 25.3 (16.7 to 36.2) |
Summary of JIA ACR core components for all subjects and each JIA category - Treatment period 1 Negative percent change indicates improvement Physician global assessment of disease activity (VAS mm) 0 (no disease activity) - 100 (very severe); Parent or subject global assessment of overall well-being (VAS mm) 0 (very well) - 100 (very poor); CHAQ (Childhood Health Assessment Questionnaire) 0 - 3 (most severe); Number of joints with active arthritis 0 - 73; Number of joints with limited range of motion 0 - 69.
| percent change | AIN457 in Treatment Period 1 |
|---|---|
| physician global assessment of disease activity | -77.4 ± 22.67 |
| parent/subject global assessment of overall well-being | -53.1 ± 58.43 |
| functional ability (CHAQ) | -53.776 ± 70.5034 |
| number of joints with active arthritis | -79.3 ± 34.86 |
| number of joints with limited range of motion | -72.5 ± 38.19 |
Median Percent Change from baseline for C-reactive protein standardized value (mg/L)
| percent change | AIN457 in Treatment Period 1 |
|---|---|
| Percent Change in C-reactive Protein Standardized Value (mg/L) | -13.587 ± 227.6901 |
JADAS change from baseline for all subjects in Treatment period 1. JADAS-27 (Juvenile Arthritis Disease Activity Score in 27 joints) ranges from 0 to 57 and JADAS-71 ranges from 0 to 101 (higher scores indicate more disease activity).
| score | AIN457 in Treatment Period 1 |
|---|---|
| JADAS-27 | -10.487 ± 7.2262 |
| JADAS-71 | -13.403 ± 9.7300 |
Enthesitis swollen joint count range is 0-16. Zero is worst, and 16 is best A total of 16 entheseal sites were assessed for the presence or absence of tenderness of enthesitis. This is the mean (SD) enthesitis count (range 0-16) for FAS subjects A zero score means no enthesitis, so a zero score is better for the patient
| Number of enthesitis events | AIN457 in Treatment Period 1 |
|---|---|
| Change From Baseline in Total Enthesitis Events - TP1 (FAS1) | -1.8 ± 2.31 |
Summary of total dactylitis count for all subjects - TP1 (FAS1) Total dactylitis count ranges from 0 to 20. A zero score means no dactylitis, so a zero score is better for the patient
| Number of dactylitis events | AIN457 in Treatment Period 1 |
|---|---|
| Change From Baseline in Total Dactylitis Count | -0.8 ± 1.83 |
Blood samples for immunogenicity (anti-AIN457 antibodies) were taken pre-dose at the scheduled time points. In addition, if a subject discontinued from the study at any time, he/she provided a sample at the last visit. All blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein. An Electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.
| Participants | AIN457 in Treatment Period 1 | AIN457 in Treatment Period 2 - Active | Placebo TP2 |
|---|---|---|---|
| Number of Participants With Anti-secukinumab Anitbodies | 0 | 0 | 0 |
Summary of pharmacokinetic concentrations - Treatment period 1
| mcg/mL | AIN457 in Treatment Period 1 |
|---|---|
| <50 kg | 30.9 ± 12.9 |
| >=50 kg | 34.6 ± 11.2 |
Summary of inactive disease status for all subjects - TP1 (FAS1) Clinical inactive disease definition was adapted from the JIA ACR criteria. All were required to be met: * No joints with active arthritis * No uveitis * CRP value within normal limits for the laboratory where tested or, if elevated, not attributable to JIA * Physician's global assessment of disease activity score ≤ 10mm * Duration of morning stiffness attributable to JIA ≤15 min
| partcipants | AIN457 in Treatment Period 1 |
|---|---|
| Number of Participants With Inactive Disease Status for All Subjects - TP1 (FAS1) | 30 (26.1 to 47.5) |
Collected over Adverse events (AEs) were collected from the time patient provided informed consent until the end of study. Serious Adverse Events (SAEs) were collected after the patient provided informed consent and until 12 weeks after last administered dose of study treatment or 30 days after the subject has stopped study participation (whichever is later). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 in Entire Treatment Period | 0/48 (0%) | 7/48 (14.6%) | 44/48 (91.7%) |
| Placebo in TP2 | 0/38 (0%) | 4/38 (10.5%) | 35/38 (92.1%) |
| Total | 0/86 (0%) | 11/86 (12.8%) | 79/86 (91.9%) |
| Event | AIN457 in Entire Treatment Period | Placebo in TP2 | Total |
|---|---|---|---|
| Acute sinusitisInfections and infestations | 0/48 | 1/38 | 1/86 |
| PneumoniaInfections and infestations | 0/48 | 1/38 | 1/86 |
| Postoperative wound infectionInfections and infestations | 0/48 | 1/38 | 1/86 |
| TonsillitisInfections and infestations | 0/48 | 1/38 | 1/86 |
| Juvenile psoriatic arthritisMusculoskeletal and connective tissue disorders | 0/48 | 1/38 | 1/86 |
| Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders | 0/48 | 1/38 | 1/86 |
| Crohn's diseaseGastrointestinal disorders | 1/48 | 0/38 | 1/86 |
| Food poisoningGastrointestinal disorders | 1/48 | 0/38 | 1/86 |
| AppendicitisInfections and infestations | 1/48 | 0/38 | 1/86 |
| FolliculitisInfections and infestations | 1/48 | 0/38 | 1/86 |
| Event | AIN457 in Entire Treatment Period | Placebo in TP2 | Total |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 16/48 | 11/38 | 27/86 |
| Upper respiratory tract infectionInfections and infestations | 10/48 | 9/38 | 19/86 |
| DiarrhoeaGastrointestinal disorders | 11/48 | 6/38 | 17/86 |
| NauseaGastrointestinal disorders | 11/48 | 8/38 | 19/86 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/48 | 4/38 | 12/86 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/48 | 5/38 | 13/86 |
| Abdominal painGastrointestinal disorders | 2/48 | 6/38 | 8/86 |
| PyrexiaGeneral disorders | 6/48 | 6/38 | 12/86 |
| HeadacheNervous system disorders | 6/48 | 6/38 | 12/86 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 7/48 | 5/38 | 12/86 |
Safety Set included subjects who received any treatment. TP1 = 86, TP2 = 75
| Age, Categorical(Participants) | All Participants |
|---|---|
| AIN457 in Treatment Period 1 — <=18 years | 86 |
| AIN457 in Treatment Period 1 — Between 18 and 65 years | 0 |
| AIN457 in Treatment Period 1 — >=65 years | 0 |
| AIN457 in Treatment Period 2 — <=18 years | 37 |
| AIN457 in Treatment Period 2 — Between 18 and 65 years | 0 |
| AIN457 in Treatment Period 2 — >=65 years | 0 |
| placebo in TP2 — <=18 years | 38 |
| placebo in TP2 — Between 18 and 65 years | 0 |
| placebo in TP2 — >=65 years | 0 |
| Age, Continuous(years) | All Participants |
|---|---|
| AIN457 in Treatment Period 1 - JIA Category: ERA | 13.7 ± 2.62 |
| AIN457 in Treatment Period 1 - JIA Category: JPsA | 12.2 ± 3.66 |
| AIN457 in Treatment Period 2 - JIA Category: ERA | 14 ± 2.46 |
| AIN457 in Treatment Period 2 - JIA Category: JPsA | 13.1 ± 3.14 |
| Placebo in TP2- JIA Category: ERA | 13 ± 2.94 |
| Placebo in TP2 - JIA Category JPsA | 10.6 ± 3.70 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| AIN457 in Treatment Period 1 - JIA Category: ERA — Female | 11 |
| AIN457 in Treatment Period 1 - JIA Category: ERA — Male | 41 |
| AIN457 in Treatment Period 1 -JIA Category: JPsA — Female | 18 |
| AIN457 in Treatment Period 1 -JIA Category: JPsA — Male | 16 |
| AIN457 in Treatment Period 2 - JIA Category: ERA — Female | 4 |
| AIN457 in Treatment Period 2 - JIA Category: ERA — Male | 18 |
| AIN457 in Treatment Period 2 -JIA Category: JPsA — Female | 9 |
| AIN457 in Treatment Period 2 -JIA Category: JPsA — Male | 6 |
| Placebo in TP2 - JIA Category: ERA — Female | 4 |
| Placebo in TP2 - JIA Category: ERA — Male | 18 |
| Placebo in TP2 - JIA Category: JPsA — Female | 7 |
| Placebo in TP2 - JIA Category: JPsA — Male | 9 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| AIN457 in Treatment Period 1 - JIA Category: ERA — American Indian or Alaska Native | 0 |
| AIN457 in Treatment Period 1 - JIA Category: ERA — Asian | 0 |
| AIN457 in Treatment Period 1 - JIA Category: ERA — Native Hawaiian or Other Pacific Islander | 0 |
| AIN457 in Treatment Period 1 - JIA Category: ERA — Black or African American | 0 |
| AIN457 in Treatment Period 1 - JIA Category: ERA — White | 51 |
| AIN457 in Treatment Period 1 - JIA Category: ERA — More than one race | 0 |
| AIN457 in Treatment Period 1 - JIA Category: ERA — Unknown or Not Reported | 1 |
| AIN457 in Treatment Period 1 - JIA Category: JPsA — American Indian or Alaska Native | 0 |
| AIN457 in Treatment Period 1 - JIA Category: JPsA — Asian | 1 |
| AIN457 in Treatment Period 1 - JIA Category: JPsA — Native Hawaiian or Other Pacific Islander | 0 |
| AIN457 in Treatment Period 1 - JIA Category: JPsA — Black or African American | 0 |
| AIN457 in Treatment Period 1 - JIA Category: JPsA — White | 31 |
| AIN457 in Treatment Period 1 - JIA Category: JPsA — More than one race | 0 |
| AIN457 in Treatment Period 1 - JIA Category: JPsA — Unknown or Not Reported | 2 |
| AIN457 in Treatment Period 2 - JIA Category: ERA — American Indian or Alaska Native | 0 |
| AIN457 in Treatment Period 2 - JIA Category: ERA — Asian | 0 |
| AIN457 in Treatment Period 2 - JIA Category: ERA — Native Hawaiian or Other Pacific Islander | 0 |
| AIN457 in Treatment Period 2 - JIA Category: ERA — Black or African American | 0 |
| AIN457 in Treatment Period 2 - JIA Category: ERA — White | 22 |
| AIN457 in Treatment Period 2 - JIA Category: ERA — More than one race | 0 |
| AIN457 in Treatment Period 2 - JIA Category: ERA — Unknown or Not Reported | 0 |
| AIN457 in Treatment Period 2 - JIA Category: JPsA — American Indian or Alaska Native | 0 |
| AIN457 in Treatment Period 2 - JIA Category: JPsA — Asian | 0 |
| AIN457 in Treatment Period 2 - JIA Category: JPsA — Native Hawaiian or Other Pacific Islander | 0 |
| AIN457 in Treatment Period 2 - JIA Category: JPsA — Black or African American | 14 |
| AIN457 in Treatment Period 2 - JIA Category: JPsA — White | 0 |
| AIN457 in Treatment Period 2 - JIA Category: JPsA — More than one race | 0 |
| AIN457 in Treatment Period 2 - JIA Category: JPsA — Unknown or Not Reported | 1 |
| Placebo in TP2 - JIA Category: ERA — American Indian or Alaska Native | 0 |
| Placebo in TP2 - JIA Category: ERA — Asian | 0 |
| Placebo in TP2 - JIA Category: ERA — Native Hawaiian or Other Pacific Islander | 0 |
| Placebo in TP2 - JIA Category: ERA — Black or African American | 0 |
| Placebo in TP2 - JIA Category: ERA — White | 21 |
| Placebo in TP2 - JIA Category: ERA — More than one race | 0 |
| Placebo in TP2 - JIA Category: ERA — Unknown or Not Reported | 1 |
| Placebo in TP2 - JIA Category: JPsA — American Indian or Alaska Native | 0 |
| Placebo in TP2 - JIA Category: JPsA — Asian | 0 |
| Placebo in TP2 - JIA Category: JPsA — Native Hawaiian or Other Pacific Islander | 1 |
| Placebo in TP2 - JIA Category: JPsA — Black or African American | 0 |
| Placebo in TP2 - JIA Category: JPsA — White | 14 |
| Placebo in TP2 - JIA Category: JPsA — More than one race | 0 |
| Placebo in TP2 - JIA Category: JPsA — Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from May 2017 to primary completion in Oct 2020, 40 months.
Results were first posted in Aug 2022, 1 year 10 months after primary completion. A results delay was requested in May 2020.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 40 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab